Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Denosumab-bbdz

(Jubbonti®)

Jubbonti®

Drug updated on 12/11/2024

Dosage FormInjection (subcutaneous; 60 mg/mL )
Drug ClassRANK ligand (RANKL) inhibitors
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture
  • Indicated for the treatment of to increase bone mass in men with osteoporosis at high risk for fracture
  • Indicated for the treatment of of glucocorticoid-induced osteoporosis in men and women at high risk for fracture
  • Indicated for the treatment of to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
  • Indicated for the treatment of to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of six systematic review(s)/meta-analysis(es). [1-5]
  • Bone Mineral Density (BMD) Improvement: Denosumab demonstrated the highest effectiveness in increasing total hip BMD in glucocorticoid-induced osteoporosis (GIOP) patients, with a surface under the cumulative ranking (SUCRA) (LS) score of 99.7%. For lumbar spine BMD improvement, raloxifene was most effective with a SUCRA score of 98.5%.
  • Fracture Risk Reduction: Denosumab significantly reduced the risk of secondary vertebral fractures in patients with osteoporosis, with a relative risk (RR) of 0.41 (95% confidence interval (CI), 0.29-0.57, p < 0.0001). However, ibandronate and teriparatide were more effective in reducing non-vertebral fracture risks in GIOP patients.
  • Fall Incidence Reduction: A pooled analysis from five placebo-controlled trials indicated that denosumab reduced the incidence of falls, with a hazard ratio of 0.79 (95% CI, 0.66-0.93, p = 0.0061).
  • Serious Adverse Events of Infection (SAEI): Denosumab-treated patients experienced a slightly increased incidence of SAEI compared to placebo (relative risk (RR) 1.21; 95% CI 1.03-1.43; p = 0.02). Compared to bisphosphonates, denosumab was associated with a higher incidence of any infections (RR 1.11; 95% CI 1.02-1.20; p = 0.02).
  • General Adverse Events: No specific adverse event rates beyond infection data were provided, and no additional significant safety concerns were highlighted for denosumab compared to placebo or bisphosphonates.
  • There is no population types or subgroups information available in the reviewed studies.